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Summary
Background—In the Carotid and Vertebral Artery Transluminal Angioplasty Study (CAVATAS),
early recurrent carotid stenosis was more common in patients assigned to endovascular treatment
than it was in patients assigned to endarterectomy (CEA), raising concerns about the long-term
effectiveness of endovascular treatment. We aimed to investigate the long-term risks of restenosis
in patients included in CAVATAS.
Methods—413 patients who were randomly assigned in CAVATAS and completed treatment for
carotid stenosis (200 patients had endovascular treatment and 213 patients had endarterectomy) had
prospective clinical follow-up at a median of 5 years and carotid duplex ultrasound at a median of 4
years. We investigated the cumulative long-term incidence of carotid restenosis after endovascular
treatment and endarterectomy, the effect of the use of stents on restenosis after endovascular
treatment, risk factors for the development of restenosis, and the effect of carotid restenosis on the
risk of recurrent cerebrovascular events. Analysis was by intention to treat. This study is registered,
number ISRCTN01425573.
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This document may be redistributed and reused, subject to certain conditions.
*Correspondence to: Martin M Brown, Box 6, The National Hospital for Neurology and Neurosurgery, Queen Square, London, WC1N
3BG, UK m.brown@ion.ucl.ac.uk.
‡CAVATAS investigators listed at end of paper
This document was posted here by permission of the publisher. At the time of deposit, it included all changes made during peer review,
copyediting, and publishing. The U.S. National Library of Medicine is responsible for all links within the document and for incorporating
any publisher-supplied amendments or retractions issued subsequently. The published journal article, guaranteed to be such by Elsevier,
is available for free, on ScienceDirect.
Sponsored document from
Lancet Neurology
Published as: Lancet Neurol. 2009 October ; 8(10): 908–917.
Sponsored D
ocum
ent 
 Sponsored D
ocum
ent 
 Sponsored D
ocum
ent
Findings—Severe carotid restenosis (≥70%) or occlusion occurred significantly more often in
patients in the endovascular arm than in patients in the endarterectomy arm (adjusted hazard ratio
[HR] 3·17, 95% CI 1·89–5·32; p<0·0001). The estimated 5-year incidence of restenosis was 30·7%
in the endovascular arm and 10·5% in the endarterectomy arm. Patients in the endovascular arm who
were treated with a stent (n=50) had a significantly lower risk of developing restenosis of 70% or
greater compared with those treated with balloon angioplasty alone (n=145; HR 0·43, 0·19–0·97;
p=0·04). Current smoking or a history of smoking was a predictor of restenosis of 70% or more (2·32,
1·19–4·54; p=0·01) and the early finding of moderate stenosis (50–69%) up to 60 days after treatment
was associated with the risk of progression to restenosis of 70% or more (3·76, 1·88–7·52; p=0·0002).
The composite endpoint of ipsilateral non-perioperative stroke or transient ischaemic attack occurred
more often in patients in whom restenosis of 70% or more was diagnosed in the first year after
treatment compared with patients without restenosis of 70% or more (5-year incidence 23% vs 11%;
HR 2·18, 1·04–4·54; p=0·04), but the increase in ipsilateral stroke alone was not significant (10%
vs 5%; 1·67, 0·54–5·11).
Interpretation—Restenosis is about three times more common after endovascular treatment than
after endarterectomy and is associated with recurrent ipsilateral cerebrovascular symptoms; however,
the risk of recurrent ipsilateral stroke is low. Further data are required from on-going trials of stenting
versus endarterectomy to ascertain whether long-term ultrasound follow-up is necessary after carotid
revascularisation.
Funding—British Heart Foundation; UK National Health Service Management Executive; UK
Stroke Association.
Introduction
Atherosclerotic carotid artery stenosis is a main cause of transient ischaemic attack and stroke.
In patients with recent cerebrovascular symptoms associated with severe carotid stenosis, the
risk of recurrent stroke can be reduced by more than a half after carotid endarterectomy.
Endovascular treatment of carotid stenosis by percutaneous transluminal balloon angioplasty
or insertion of a stent is an alternative to endarterectomy. However, a recent meta-analysis
found a higher risk of stroke or death within 30 days after endovascular treatment than after
endarterectomy, with some uncertainty about this result, and endarterectomy has remained the
treatment of choice for carotid stenosis.
The long-term efficacy of endovascular treatment for preventing stroke is unknown. The
Carotid and Vertebral Artery Transluminal Angioplasty Study (CAVATAS) was a large
multicentre randomised trial with the aim of comparing endovascular treatment (angioplasty
with or without stenting) with endarterectomy in patients with predominantly symptomatic
moderate or severe carotid stenosis. The initial report from CAVATAS showed no difference
in the primary endpoint of disabling stroke or death, or in ipsilateral stroke in the first 3 years
after treatment. However, 1 year after treatment, severe stenosis or occlusion of the carotid
artery was seen more often after endovascular treatment than after endarterectomy. Concern
remained that the proportion of patients with restenosis after endovascular treatment would
increase over time and that the high rate of restenosis might restrict the long-term efficacy of
endovascular treatment for stroke prevention.
The long-term follow-up of patients in CAVATAS has recently been completed, 10 years after
the last patient was randomised. In the analysis of clinical outcome events, which is reported
in this issue, there was a non-significant difference in the incidence of ipsilateral non-
perioperative stroke or TIA that favoured endarterectomy (hazard ratio 1·29, 95% CI 0·78–
2·14).
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In this follow-up study, we analysed the available long-term carotid ultrasound data from
CAVATAS with the following aims: to compare the cumulative long-term incidence of carotid
restenosis after endovascular treatment and endarterectomy; to investigate the effect of the use
of stents on restenosis after endovascular treatment; to identify risk factors for the development
of restenosis; and to investigate the effect of carotid restenosis on the risk of recurrent
cerebrovascular events.
Methods
Patients
CAVATAS was a randomised, open, multicentre trial with outcome adjudication by
investigators masked to treatment allocation. The trial methodology has been described in
detail in the initial report. For the present study, we selected patients who had completed
endovascular treatment or endarterectomy of the stenotic internal carotid artery and had follow-
up data from carotid duplex ultrasound. The study population differs from that in a previous
report on residual and early recurrent stenosis in CAVATAS, which was restricted to ultrasound
examinations done 1 month and 1 year after treatment and included both patients who had
completed treatment and those with incomplete treatment. A few patients with stenosis of the
common carotid artery were enrolled in CAVATAS, but these patients were excluded from
this analysis owing to the absence of uniform criteria for grading stenosis of the common carotid
artery with ultrasound.
Procedures
In the first phase of the study, patients randomly assigned to endovascular treatment were
treated by percutaneous transluminal angioplasty with balloon catheters. Stents became
available in the second half of the recruitment period; collaborating interventionalists were
subsequently permitted to use Wallstents, Palmaz, and Strecker stents at their discretion. Stents
were most commonly deployed if the reduction in stenosis achieved with previous balloon
angioplasty was unsatisfactory. In a few patients, primary stenting was done without first
attempting full balloon dilatation. Endovascular treatment was defined as complete if a balloon
was dilated across the stenosis or a stent was successfully deployed. Collaborating surgeons
used their preferred technique for endarterectomy, either with primary closure of the
arteriotomy or closure with surgical patches. Completed endarterectomy was defined as an
operation in which removal of the atheromatous plaque and closure of the arteriotomy was
achieved.
The protocol recommended endovascular or surgical treatment for recurrent stenosis after
initial treatment only if the patient developed relevant new symptoms. Asymptomatic
restenosis was not deemed an indication for re-treatment because the risk of recurrent
cerebrovascular events after restenosis was unknown. No recommendation as to the type of
retreatment (endovascular or endarterectomy) was made.
Patients in CAVATAS were examined at baseline by neurologically trained investigators not
involved in the endovascular treatment or endarterectomy and followed up at 1 month, 6
months, and 1 year after treatment and annually thereafter. There was no predefined maximum
length of follow-up, but centres were encouraged to follow up patients for as long as the centre
and individual patients were willing to do so. Follow-up ended in 2007, 10 years after the end
of recruitment. Outcome events, including stroke, transient ischaemic attack, and amaurosis
fugax, were independently adjudicated by use of standard definitions in the central trial office
by two investigators (LHB and JE) who were masked to treatment allocation. Amaurosis fugax
was included in the category of transient ischaemic attack. In case of disagreement, a third
independent investigator made the final adjudication.
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Carotid imaging before randomisation required either selective digital subtraction angiography
(DSA) or consistent findings on carotid duplex ultrasound and non-invasive angiography
(magnetic resonance angiography [MRA] or computer tomography angiography [CTA]).
Assessment of the rate of restenosis after treatment was a predefined objective of CAVATAS.
The protocol included carotid duplex ultrasound follow-up 1 year after treatment and every
year thereafter. In many centres, additional ultrasound examinations were done at 1 and 6
months after treatment. In the event of recurrent cerebrovascular events during follow-up,
additional carotid imaging was done at the discretion of the local investigators.
The peak systolic velocities of the common carotid and the internal carotid arteries and the end
diastolic velocity of the internal carotid artery were recorded with carotid duplex ultrasound
and reported to the central trial office. One investigator (LHB), who was masked to treatment
allocation, ascertained the degree of stenosis during follow-up, on the basis of predefined,
standardised flow velocity criteria, which equate well with the severity of carotid stenosis
measured on catheter angiography with the North American Symptomatic Carotid
Endarterectomy Trial (NASCET) method (table 1). The severity of stenosis seen on carotid
angiography (MRA, CTA, or DSA) done in addition to ultrasound for recurrent symptoms was
measured according to the NASCET method. A second investigator made the final
classification of stenosis when measurements from more than one imaging modality were
conflicting. Stenosis was classified as: not significant (0–49% stenosis), moderate (50–69%),
severe (70–99%), or occluded (100%). Velocity measurements were not available for a few
centres, and the degree of stenosis reported by the local ultrasonographer at the participating
centre was used in these cases.
The primary outcome of this analysis (≥70% restenosis) was defined as any residual or recurrent
severe stenosis or occlusion of the carotid artery detected at any stage during follow-up after
completed treatment. The secondary outcome (≥50% restenosis) was defined as any residual
or recurrent moderate or severe carotid stenosis or occlusion after completed treatment. We
compared the incidence of the primary and secondary outcomes between patients randomly
assigned to endovascular treatment versus endarterectomy and between patients who were
treated with balloon angioplasty alone (without use of a stent) and patients treated with a stent
in those randomly assigned to endovascular treatment. Because the use of stents was not
randomised in CAVATAS, the analysis of patients treated with stents and those treated with
balloon angioplasty is a comparison of two subsets of patients in the endovascular treatment
arm and is based on post-randomisation information (ie, which endovascular treatment
technique the patient actually received).
We investigated whether the following baseline characteristics were independently associated
with restenosis of 70% or more: age at randomisation, sex, smoking, hypertension,
hypercholesterolaemia, diabetes, history of coronary heart disease, history of peripheral
vascular disease, and the degree of ipsilateral carotid stenosis at randomisation according to
the NASCET method. In a separate analysis, we assessed whether the moderate (50–69%)
residual or early recurrent stenosis diagnosed up to 60 days after treatment was associated with
long-term risk of restenosis of 70% or more.
To assess the association between restenosis and recurrent cerebrovascular events during long-
term follow-up, we compared the incidence of the composite endpoint of ipsilateral stroke or
transient ischaemic attack, and only ipsilateral stroke between patients with and without 70%
or more restenosis diagnosed in the first year after treatment. Only cerebrovascular events that
occurred after the first 1-year carotid duplex ultrasound that confirmed 70% or more restenosis
or less than 70% restenosis were included. Events that occurred within 30 days of initial
treatment were excluded because they were defined as perioperative complications of
treatment. To ascertain the natural risk of cerebrovascular events with restenosis, patients who
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had endovascular treatment or endarterectomy for recurrent stenosis after their initial treatment
were censored at the time of retreatment.
Statistical analysis
Data analysis was primarily done according to the randomly assigned treatment (intention to
treat). A second, per-protocol analysis, which excluded patients who did not receive their
assigned treatment, was also done. The incidence of restenosis after stenting compared with
angioplasty alone could only be calculated from the per-protocol analysis. To check whether
the length of carotid duplex ultrasound follow-up was similar in both treatment arms, the time
to censoring was compared by use of the log-rank test. When comparing the risks of 70% or
more and 50% or more restenosis between the treatment groups, the exact date of restenosis
was not known (ie, restenosis was only known to have occurred at some point between the
previous normal ultrasound and the examination at which restenosis was diagnosed). Data in
this form are known as interval-censored data and require appropriate analysis methods.
Because the scheduled ultrasound examinations did not always take place at the planned times,
and because some patients missed their scheduled appointments, an analysis method in which
observation times can differ among individuals was used. This method assumes proportional
hazards and is based on a non-linear model for a set of binary response variables (a generalised
non-linear model). The resulting parameter estimates, such as the treatment effect estimate,
can be interpreted as log hazard ratios. For these models, patients without restenosis were
censored at the time of their last carotid duplex ultrasound. Censoring was assumed to be non-
informative. The proportionality of hazards was assessed by interactions with follow-up time
periods. There was some suggestion that the hazard ratio of endovascular treatment versus
carotid endarterectomy for the 50% or greater restenosis outcome might decrease over the
course of the study, but the test for non-proportionality of hazards was not significant (p=0·1).
The hazard ratios and their 95% CIs throughout the follow-up period are reported. Life-table
analyses were used to estimate the cumulative incidences of restenosis at the scheduled
examination times after treatment, with predefined interest in the incidences at 1 year and 5
years. For the patients diagnosed with restenosis who were missing from the previous scheduled
ultrasound examination, restenosis was assumed to have occurred during the life-table interval,
half way between diagnosis and the last available normal ultrasound examination. Cumulative
incidences for later than 5 years after treatment were not calculated because the patients who
continued to have ultrasound follow-up was small. Multivariable generalised non-linear
models that were adjusted for treatment were used to test whether 70% or more restenosis
during follow-up was associated with the above defined baseline covariates and early 50–69%
stenosis. Hazard ratios calculated for restenosis were adjusted for age, sex, and the independent
baseline predictors of restenosis identified in the multivariable model. Cox regression analysis
was used to compare time until ipsilateral cerebrovascular events between patients with and
without 70% or more restenosis detected within the first year after treatment (including
ultrasound examinations done up to 1·5 years after treatment because the scheduled 1-year
examinations did not always take place exactly 1 year after treatment) and were adjusted for
allocated treatment, age, and sex. This study is registered, number ISRCTN01425573.
Role of the funding source
The study sponsors had no role in study design, data collection, data analysis, data
interpretation, or the writing of the report. The corresponding author had full access to all the
data in the study and had final responsibility for the decision to submit for publication.
Results
Between March 1, 1992, and July 31, 1997, 504 patients were randomly assigned to
endovascular treatment (n=251) or endarterectomy (n=253) by telephone or fax from the
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randomisation service at the Oxford Clinical Trials Unit. Figure 1 shows the trial profile. Of
the patients randomly assigned to endovascular treatment, 240 had initial treatment as
allocated, six crossed over to endarterectomy, and five received neither endovascular treatment
nor endarterectomy. Among the patients randomly assigned to endarterectomy, 246 received
the treatment they were assigned, two crossed over to endovascular treatment, and five received
neither of the two treatments. Endovascular treatment was not completed in 27 of the patients
assigned to this treatment and in one patient who was allocated to endarterectomy but crossed
over to the other treatment arm. Endarterectomy was completed in each patient who had
surgery. The reasons for not receiving the randomly allocated treatment or for incomplete
treatment were specified in the initial report. One patient in each treatment arm was treated for
stenosis of the common carotid artery and was thus excluded from the present analysis. Among
the patients who completed treatment, 18 patients in the endovascular group and 33 patients
in the endarterectomy group did not have carotid duplex ultrasound follow-up. Therefore, the
intention-to-treat analysis of those patients who completed treatment comprised 200 patients
who had endovascular treatment and 213 patients who had endarterectomy; the per-protocol
analysis comprised 195 patients treated with the endovascular approach (angioplasty alone
n=145; stenting n=50) and 212 patients treated with endarterectomy.
Baseline clinical characteristics of patients included in the present analysis of restenosis were
similar to the whole population of CAVATAS and there were no significant differences
between those assigned to endovascular treatment and those assigned to endarterectomy (table
2). More than 90% of patients had a cerebrovascular event in the territory of the ipsilateral
carotid artery within 6 months before randomisation. The duration of the carotid duplex
ultrasound follow-up (median 4·0 [IQR 1·9–5·4] years in the endovascular arm vs 4·1 [1·3–
5·5] years in the surgery arm) and clinical follow-up (5·0 [3·0–6·2] years vs 5·0 [2·9–6·1] years)
were similar in the two arms, and there was no evidence of a difference in time to censoring
(log rank p=0·9). In the endovascular arm, patients who were treated with stenting were less
likely to have a history of peripheral vascular disease than were patients treated with
angioplasty alone (4 of 50 [8%] vs 38 of 145 [26%]; p=0·005). Other clinical characteristics
were similar between the two endovascular treatment subgroups.
The primary outcome (≥70% restenosis) occurred significantly more often in patients who had
endovascular treatment than in patients who had endarterectomy (53 vs 20 patients [adjusted
HR 3·17, 95% CI 1·89–5·32; p<0·0001]; table 3, figure 2). 1 and 5 years after treatment, the
cumulative incidences of 70% or greater restenosis were 21·7% (SE 3·0) and 30·7% (3·7),
respectively, in the endovascular arm and 7·5% (1·9) and 10·5% (2·4), respectively, in the
surgery arm.
The secondary outcome (≥50% restenosis) also occurred more frequently in the endovascular
arm than in the surgery arm (109 vs 59; adjusted HR 2·58, 95% CI 1·87–3·55; p<0·0001). The
cumulative 1-year and 5-year incidences of 50% or more restenosis were 48·5% (SE 3·6) and
58·6% (3·9), respectively, in the endovascular arm, compared with 20·7% (2·9) and 31·5%
(3·5), respectively, in the endarterectomy group.
Similar results were obtained in the secondary per-protocol analysis: adjusted HR 3·40 (95%
CI 2·10–5·77) for 70% or more restenosis and 2·72, (1·97–3·75) for 50% or more restenosis
after endovascular treatment compared with endarterectomy.
Of the patients who were assigned to endovascular treatment, the risks of 70% or more
restenosis (adjusted HR 0·43, 0·19–0·97; p=0·04) and 50% or more restenosis (0·37, 0·21–0·62;
p=0·0003) were significantly lower in those patients treated with a stent than in those treated
by angioplasty alone (table 4, figure 2).
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Of all the covariates tested at baseline, smoking (either at baseline or in the past) was the only
independent predictor of 70% or more restenosis (HR 2·32, 95% CI 1·19–4·54; p=0·01
[adjusted for treatment in current or ex-smokers compared with those who never smoked]).
There was no significant interaction between treatment and the effect of smoking on restenosis
(p=0·86). Residual or recurrent stenosis of between 50–69% seen on early ultrasound at any
time up to 60 days after treatment was associated with a significant increase in the risk of
subsequent progression to 70% or more restenosis (HR 3·76, 95% CI 1·88–7·52; p=0·0002)
compared with 0–49% stenosis seen on early carotid duplex ultrasound, adjusted for treatment.
There was no significant interaction between treatment and the effect of early moderate stenosis
on progression to severe restenosis or occlusion (p=0·91).
The incidence of ipsilateral non-perioperative stroke or transient ischaemic attack was
significantly higher in patients with 70% or more restenosis that was diagnosed within the first
year after treatment compared with those who had less than 70% restenosis in the first year.
10 of 52 patients (cumulative 5-year incidence 22·7%) with 70% or more restenosis had
subsequent ipsilateral cerebro-vascular events compared with 35 of 344 patients (10·9%) with
less than 70% restenosis (adjusted HR 2·18, 95% CI 1·04–4·54; p=0·04; table 5, figure 3). In
three patients without 70% or more restenosis in the first year who had an ipsilateral
cerebrovascular event, carotid duplex ultrasound done after the event detected severe
restenosis. There was a higher incidence of ipsilateral stroke in patients with 70% or more
restenosis (four patients [9·7%]) compared with patients without 70% or more restenosis (17
patients [5·4%]) but the difference was not statistically significant (1·67, 0·54–5·11; p=0·4).
Seven patients in the endovascular arm had repeat endovascular treatment for restenosis (6
patients who were symptomatic and 1 patient who was asymptomatic). One of these patients
had an ipsilateral non-disabling stroke during the procedure. In the endarterectomy arm, one
patient had repeat endarterectomy for symptomatic restenosis and one patient had repeat
endarterectomy for asymptomatic restenosis; these were done without complications.
Discussion
This study provides several key findings: the long-term risk of developing severe (≥70%)
carotid restenosis or occlusion was about three times higher after endovascular treatment than
it was after endarterectomy; smoking and moderate residual or early recurrent stenosis were
independent predictors of severe carotid restenosis or occlusion during follow-up; and severe
carotid restenosis or occlusion was associated with an increased risk of ipsilateral
cerebrovascular events during follow-up.
CAVATAS was a large randomised trial to assess the long-term risk of restenosis after
revascularisation of symptomatic carotid stenosis. The previous large trials of endarterectomy
for symptomatic stenosis (ie, NASCET and the European Carotid Surgery Trial [ECST]) did
not include carotid ultrasound follow-up. In CAVATAS, 31% of patients in the endovascular
group developed severe (≥70%) carotid restenosis or occlusion by the fifth year after treatment
compared with only 11% of the patients treated with endarterectomy. The secondary outcome
(moderate or worse [≥50%] restenosis) was estimated to occur in 59% of patients in the first
5 years after endovascular treatment compared with 32% of patients in the first 5 years after
endarterectomy. The cumulative long-term incidence of restenosis seen in the endarterectomy
arm of CAVATAS was similar to that seen in case series, in which incidences of up to 9% for
severe restenosis or occlusion at 5 years and up to 32% for moderate or worse restenosis at 7
years after treatment were reported.
Most of the patients randomly assigned to endovascular treatment in CAVATAS had
angioplasty without stents. In the endovascular arm, the long-term incidences of 70% or more
and 50% or more restenosis were lower after stenting than they were after balloon angioplasty
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alone. However, restenosis among patients who had a stent in CAVATAS was still more
common than it was in case series of primary stenting, which have reported moderate restenosis
in up to 16% of patients and severe restenosis in 6% of patients at 5 years. This might indicate
better ascertainment of the restenosis outcome within the context of a clinical trial and
highlights differences in patient selection, stenting technique (in CAVATAS, most stenting
procedures were done after balloon dilatation was attempted), and ultrasound criteria for
grading restenosis. Our study therefore provides some evidence that stenting might be superior
to angioplasty alone for the prevention of restenosis. The investigators in one trial that
compared primary stenting with endarterectomy have published the incidence of carotid
restenosis after a comparatively short follow-up period: the 2-year cumulative risk of severe
restenosis or occlusion was 11% after stenting compared with 5% after endarterectomy. Long-
term follow-up data on restenosis from recent trials of primary stenting versus endarterectomy
are needed to assess the long-term efficacy of carotid stenting for the prevention of restenosis.
Restenosis up to about 2 years after endarterectomy is commonly attributed to neointimal
hyperplasia, whereas recurrent atherosclerosis is thought to cause later restenosis. Neointimal
hyperplasia and smooth muscle cell proliferation have also been seen in a patient in CAVATAS
who had symptomatic restenosis after endovascular treatment. This observation, and the fact
that in both arms of CAVATAS most restenoses occurred within the first year of treatment,
suggests that similar mechanisms are involved in restenosis after endovascular treatment and
endarterectomy.
We found that smoking at study entry or past smoking was an independent predictor of
restenosis. There was no significant interaction between treatment received and smoking for
the prediction of restenosis, suggesting that smoking had a similar effect in both treatment
arms. Smoking has previously been indentified as a predictor of restenosis after
endarterectomy. Smoking did not predict restenosis after carotid stenting in previous case
series, but these studies had median follow-up times of only 2 years or less. Additionally,
patients in whom moderate residual or early recurrent stenosis was found within 60 days of
treatment were at significantly elevated risk for progression to severe restenosis or occlusion
during follow-up compared with patients without significant early stenosis. These observations
might be helpful when selecting patients for long-term ultrasound follow-up.
Severe carotid restenosis or occlusion diagnosed within the first year after treatment was
associated with an increased risk of subsequent ipsilateral cerebrovascular events (ipsilateral
stroke or transient ischaemic attack) during long-term follow-up. There was no significant
increase in the risk of ipsilateral stroke in patients with 70% or more restenosis compared with
those with less than 70% restenosis; however, owing to the small number of patients that
reached this endpoint, the confidence interval for the estimated hazard ratio was wide. As
reported in the companion article on the long-term clinical outcome of CAVATAS, there were
more patients with non-perioperative ipsilateral stroke or transient ischaemic attack (HR 1·29,
95% CI 0·78–2·14) and more patients with non-perioperative ipsilateral stroke (1·22, 0·59–
2·54) in the endovascular arm than there were in the endarterectomy arm during follow-up,
although these differences were not statistically significant. The increase in events in the
endovascular arm might be partly explained by the high incidence of restenosis after
endovascular treatment.
Because more than half of the recurrent cerebrovascular symptoms that occurred in patients
with severe restenosis were transient, and because of the small number of outcome events, our
data do not support routine elective carotid reinterventional treatment for asymptomatic severe
carotid restenosis after endovascular treatment or endarterectomy. Any decision on potential
reintervention in patients with asymptomatic severe carotid restenosis seen on routine carotid
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duplex ultrasound or angiographic screening should take into account the low risk of ipsilateral
stroke in these patients (about 2% per year in our study).
Our study has several limitations. Owing to financial constraints and the restricted availability
of ultrasound at the beginning of the trial, ultrasound follow-up was not available or was only
done at 1 year after treatment at some centres. However, at the centres that recruited the most
patients, annual ultrasound follow-up was usually continued after 1 year, and the median length
of follow-up in CAVATAS is similar to that reported in open registries of the long-term risk
of carotid restenosis. Therefore, the performance of ultrasound follow-up and its duration
primarily depended on the centre where the patient was randomly assigned, rather than
selection criteria at the patient level. Because equal proportions of patients were randomly
assigned to each arm at the centres, any concerns about selection bias in the comparison of
restenosis between treatments might be reduced. Stenting in the endovascular group was not
randomly assigned in the trial, and only a few patients were treated with stents. Although the
baseline characteristics were similar in those patients treated with and those treated without
stents (with the exception of a history of peripheral artery disease), differences in unmeasured
risk factors might have been present. Additionally, most of the patients treated with stents
received them after balloon angioplasty had not reduced the degree of stenosis sufficiently.
The primary carotid stenosis in these patients might therefore have differed from the stenosis
in the patients in whom balloon angioplasty was successful, in a way that might have
systematically altered their risk of restenosis. The strength of evidence from CAVATAS with
regard to the efficacy of stenting for preventing restenosis compared with angioplasty alone is
therefore limited. Without broadly accepted criteria for ultrasound of stented carotid arteries,
and for reasons of consistency with previous reports from CAVATAS, the same ultrasound
criteria were applied in those patients treated with and without stents. This approach might
have led to the overestimation of restenosis in the patients who received stents because of
reduced compliance in the vessel wall.
Our study was underpowered to detect any effect of carotid restenosis on ipsilateral stroke.
Optimum medical treatment has improved since CAVATAS was designed. In particular, the
use of lipid-lowering therapy in patients with symptomatic carotid artery stenosis is likely to
have increased in recent years, and antiplatelet treatment regimens to be given around the time
of stenting have been developed. These factors might possibly influence the risk of restenosis
after treatment, and information on lipid-lowering therapy was not systematically collected in
CAVATAS. Finally, primary stenting has replaced balloon angioplasty as the endovascular
treatment of choice for severe carotid stenosis.
In conclusion, restenosis is about three times more common after endovascular treatment than
it is after endarterectomy and seems to cause recurrent cerebrovascular events. More data from
ongoing randomised trials that compare primary carotid stenting with endarterectomy are
needed to assess whether modern stenting techniques are as effective as surgery for preventing
restenosis in the long term and to determine accurately the relation between restenosis and
recurrent stroke over time. In particular, whether patients treated with endovascular methods
require long-term follow-up with carotid duplex ultrasound to detect restenosis before it
becomes symptomatic remains uncertain.
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Figure 1.
Trial profile
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Figure 2.
Cumulative incidence of restenosis estimated from life-table analysis
Data are the cumulative incidence of restenosis after endovascular treatment compared with
endarterectomy (A,B), and for stenting compared with balloon angioplasty alone (C,D),
respectively, to the end of available follow-up, from generalised non-linear models. (A,C) 70%
or more restenosis. (B,D) 50% or more restenosis. Vertical bars are SE.
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Figure 3.
Kaplan–Meier estimates of ipsilateral stroke or transient ischaemic attack
(A) Ipsilateral stroke or transient ischaemic attack. (B) Ipsilateral stroke. Hazard ratio
calculated from adjusted Cox hazard ratio for ipsilateral cerebrovascular events during follow-
up in patients with 70% or more restenosis in the first year after treatment compared with
patients with less than 70% restenosis in the first year after treatment to the end of available
follow-up. Time is from the first ultrasound examination done within the first year after
treatment that confirmed 70% or more restenosis or less than 70% restenosis.
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Table 1
Duplex ultrasound velocity criteria equivalent to NASCET angiography measures used for grading the degree of carotid
stenosis
PSV ICA (m/s) EDV ICA (m/s) PSV ICA/PSV CCA
0–29% <1·1 <0·4 <3·2
30–49% 1·1–1·3 <0·4 <3·2
50–59% >1·3–2·1 <0·4 <3·2
60–69% >1·3–2·1 0·4–1·1 3·2–4·0
70–79% >2·1 >1·1–1·4 >4·0
80–95% >2·1 >1·4 >4·0
96–99% String flow String flow String flow
100% Occluded Occluded Occluded
PSV=peak systolic velocity. ICA=internal carotid artery. EDV=end diastolic velocity. CCA=common carotid artery. NASCET=North American
Symptomatic Carotid Endarterectomy Trial.
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Table 3
Carotid restenosis after endovascular treatment compared with endarterectomy
Endovascular treatment (n=200) Endarterectomy (n=213)
≥70% restenosis
Number of patients with outcome 53 20
Cumulative 1-year incidence* 21·7% (3·0) 7·5% (1·9)
Cumulative 5-year incidence* 30·7% (3·7) 10·5% (2·4)
Unadjusted hazard ratio† 3·14, 1·87–5·26‡
Adjusted hazard ratio† 3·17, 1·89–5·32‡
≥50% restenosis
Number of patients with outcome 109 59
Cumulative 1-year incidence* 48·5% (3·6) 20·7% (2·9)
Cumulative 5-year incidence* 58·6% (3·9) 31·5% (3·5)
Unadjusted hazard ratio† 2·57, 1·87–3·53‡
Adjusted hazard ratio† 2·58, 1·87–3·55‡
Data are number, cumulative incidence (SE), or hazard ratio, 95% CI.
*
Cumulative incidence of restenosis estimated from life-table analysis.
†
Restenosis after endovascular treatment compared with carotid endarterectomy to the end of available follow-up (generalised non-linear model:
unadjusted and adjusted for sex, age, and smoking).
‡
p<0·0001.
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Table 4
Carotid restenosis after endovascular treatment with stenting compared with
balloon angioplasty alone
Stenting (n=50) Angioplasty (n=145)
≥70% restenosis
Number of patients with outcome 7 46
Cumulative 1-year incidence* 13·1% (5·0) 25·3% (3·7)
Cumulative 5-year incidence* 16·6% (5·9) 36·2% (4·5)
Unadjusted hazard ratio† 0·41, 0·19–0·92‡
Adjusted hazard ratio† 0·43, 0·19–0·97§
≥50% restenosis
Number of patients with outcome 16 93
Cumulative 1-year incidence* 23·0% (6·1) 58·8% (4·2)
Cumulative 5-year incidence* 36·6% (8·1) 68·1% (4·3)
Unadjusted hazard ratio† 0·36, 0·21–0·61¶
Adjusted hazard ratio† 0·37, 0·21–0·62‖
Data are number, cumulative incidence (SE), or hazard ratio, 95% CI.
*
Cumulative incidence of restenosis estimated from life-table analysis.
†
Restenosis after stenting compared with balloon angioplasty alone to the end of available follow-up (generalised non-linear model: unadjusted and
adjusted for sex, age, and smoking).
‡
p=0·03.
§
p=0·04.
¶
p=0·0002.
‖
p=0·0003.
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Table 5
Ipsilateral non-perioperative cerebrovascular events during follow-up in patients
with 70% or more restenosis compared with patients with less than 70% restenosis
diagnosed in the first year after treatment
≥70% restenosis (n=52) <70% restenosis (n=344)
Ipsilateral stroke or transient ischaemic attack
Number of patients with endpoint 10 35
Cumulative 5-year incidence* 22·7% (6·4) 10·9% (1·9)
Unadjusted hazard ratio† 2·19, 1·08–4·43‡
Adjusted hazard ratio† 2·18, 1·04–4·54§
Ipsilateral stroke
Number of patients with endpoint 4 17
Cumulative 5-year incidence* 9·7% (4·7) 5·4% (1·4)
Unadjusted hazard ratio† 1·73, 0·58–5·16¶
Adjusted hazard ratio† 1·67, 0·54–5·11‖
Data are number, cumulative incidence (SE), or hazard ratio, 95% CI.
*
Cumulative incidence of events estimated from Kaplan–Meier analysis.
†
Cox hazard ratio for ipsilateral cerebrovascular events during follow-up in patients with 70% or more restenosis in the first year after treatment compared
with patients with less than 70% restenosis in the first year after treatment to the end of available follow-up: unadjusted and adjusted for treatment, sex,
and age. Only events that occurred after the first ultrasound examination to show 70% or more stenosis or less than 70% restenosis are included.
‡
p=0·03.
§
p=0·04.
¶
p=0·3.
‖
p=0·4.
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